vs
8X8 INC（EGHT）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
8X8 INC的季度营收约是Vericel Corp的2.0倍（$185.1M vs $92.9M），Vericel Corp净利率更高（25.0% vs 2.8%，领先22.3%），Vericel Corp同比增速更快（23.3% vs 3.4%），8X8 INC自由现金流更多（$19.1M vs $12.8M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 1.6%）
8x8 Inc是源自美国的企业级云通信与客户体验软件服务商，依托云架构为企业提供统一通信、呼叫中心及通信平台即服务（CPaaS）等产品方案，公司总部位于加利福尼亚州坎贝尔，其股票在纳斯达克交易所挂牌交易。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
EGHT vs VCEL — 直观对比
营收规模更大
EGHT
是对方的2.0倍
$92.9M
营收增速更快
VCEL
高出19.8%
3.4%
净利率更高
VCEL
高出22.3%
2.8%
自由现金流更多
EGHT
多$6.3M
$12.8M
两年增速更快
VCEL
近两年复合增速
1.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $92.9M |
| 净利润 | $5.1M | $23.2M |
| 毛利率 | 63.9% | 78.7% |
| 营业利润率 | 5.2% | 24.1% |
| 净利率 | 2.8% | 25.0% |
| 营收同比 | 3.4% | 23.3% |
| 净利润同比 | 68.4% | 17.3% |
| 每股收益（稀释后） | $0.04 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EGHTVCEL
| Q4 25 | $185.1M | $92.9M | ||
| Q3 25 | $184.1M | $67.5M | ||
| Q2 25 | $181.4M | $63.2M | ||
| Q1 25 | $177.0M | $52.6M | ||
| Q4 24 | $178.9M | $75.4M | ||
| Q3 24 | $181.0M | $57.9M | ||
| Q2 24 | $178.1M | $52.7M | ||
| Q1 24 | $179.4M | $51.3M |
净利润EGHTVCEL
| Q4 25 | $5.1M | $23.2M | ||
| Q3 25 | $767.0K | $5.1M | ||
| Q2 25 | $-4.3M | $-553.0K | ||
| Q1 25 | $-5.4M | $-11.2M | ||
| Q4 24 | $3.0M | $19.8M | ||
| Q3 24 | $-14.5M | $-901.0K | ||
| Q2 24 | $-10.3M | $-4.7M | ||
| Q1 24 | $-23.6M | $-3.9M |
毛利率EGHTVCEL
| Q4 25 | 63.9% | 78.7% | ||
| Q3 25 | 64.8% | 73.5% | ||
| Q2 25 | 66.4% | 73.7% | ||
| Q1 25 | 67.8% | 69.0% | ||
| Q4 24 | 67.7% | 77.6% | ||
| Q3 24 | 68.1% | 71.9% | ||
| Q2 24 | 67.9% | 69.5% | ||
| Q1 24 | 68.2% | 68.9% |
营业利润率EGHTVCEL
| Q4 25 | 5.2% | 24.1% | ||
| Q3 25 | 2.9% | 5.1% | ||
| Q2 25 | 0.3% | -3.2% | ||
| Q1 25 | 0.2% | -24.3% | ||
| Q4 24 | 5.0% | 24.5% | ||
| Q3 24 | 4.0% | -4.3% | ||
| Q2 24 | -0.8% | -11.5% | ||
| Q1 24 | -7.9% | -10.7% |
净利率EGHTVCEL
| Q4 25 | 2.8% | 25.0% | ||
| Q3 25 | 0.4% | 7.5% | ||
| Q2 25 | -2.4% | -0.9% | ||
| Q1 25 | -3.1% | -21.4% | ||
| Q4 24 | 1.7% | 26.3% | ||
| Q3 24 | -8.0% | -1.6% | ||
| Q2 24 | -5.8% | -8.9% | ||
| Q1 24 | -13.1% | -7.5% |
每股收益（稀释后）EGHTVCEL
| Q4 25 | $0.04 | $0.46 | ||
| Q3 25 | $0.01 | $0.10 | ||
| Q2 25 | $-0.03 | $-0.01 | ||
| Q1 25 | $-0.04 | $-0.23 | ||
| Q4 24 | $0.02 | $0.40 | ||
| Q3 24 | $-0.11 | $-0.02 | ||
| Q2 24 | $-0.08 | $-0.10 | ||
| Q1 24 | $-0.20 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $86.9M | $137.5M |
| 总债务越低越好 | $321.2M | — |
| 股东权益账面价值 | $142.9M | $354.6M |
| 总资产 | $661.5M | $488.0M |
| 负债/权益比越低杠杆越低 | 2.25× | — |
8季度趋势，按日历期对齐
现金及短期投资EGHTVCEL
| Q4 25 | $86.9M | $137.5M | ||
| Q3 25 | $75.9M | $135.4M | ||
| Q2 25 | $81.3M | $116.9M | ||
| Q1 25 | $88.0M | $112.9M | ||
| Q4 24 | $104.2M | $116.2M | ||
| Q3 24 | $117.4M | $101.7M | ||
| Q2 24 | $130.8M | $102.5M | ||
| Q1 24 | $117.3M | $110.6M |
总债务EGHTVCEL
| Q4 25 | $321.2M | — | ||
| Q3 25 | $325.8M | — | ||
| Q2 25 | $335.4M | — | ||
| Q1 25 | $350.0M | — | ||
| Q4 24 | $364.5M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $409.7M | — |
股东权益EGHTVCEL
| Q4 25 | $142.9M | $354.6M | ||
| Q3 25 | $133.2M | $321.9M | ||
| Q2 25 | $128.2M | $306.8M | ||
| Q1 25 | $122.2M | $295.5M | ||
| Q4 24 | $113.0M | $292.0M | ||
| Q3 24 | $109.8M | $257.5M | ||
| Q2 24 | $104.6M | $243.0M | ||
| Q1 24 | $102.0M | $233.9M |
总资产EGHTVCEL
| Q4 25 | $661.5M | $488.0M | ||
| Q3 25 | $670.8M | $453.3M | ||
| Q2 25 | $684.3M | $435.6M | ||
| Q1 25 | $683.2M | $424.6M | ||
| Q4 24 | $698.2M | $432.7M | ||
| Q3 24 | $740.1M | $390.4M | ||
| Q2 24 | $755.7M | $376.8M | ||
| Q1 24 | $756.0M | $356.7M |
负债/权益比EGHTVCEL
| Q4 25 | 2.25× | — | ||
| Q3 25 | 2.45× | — | ||
| Q2 25 | 2.62× | — | ||
| Q1 25 | 2.86× | — | ||
| Q4 24 | 3.23× | — | ||
| Q3 24 | 3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 4.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.7M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $19.1M | $12.8M |
| 自由现金流率自由现金流/营收 | 10.3% | 13.8% |
| 资本支出强度资本支出/营收 | 0.9% | 2.4% |
| 现金转化率经营现金流/净利润 | 4.07× | 0.65× |
| 过去12个月自由现金流最近4个季度 | $43.8M | $24.7M |
8季度趋势，按日历期对齐
经营现金流EGHTVCEL
| Q4 25 | $20.7M | $15.0M | ||
| Q3 25 | $8.8M | $22.1M | ||
| Q2 25 | $11.9M | $8.2M | ||
| Q1 25 | $5.9M | $6.6M | ||
| Q4 24 | $27.2M | $22.2M | ||
| Q3 24 | $12.3M | $10.2M | ||
| Q2 24 | $18.1M | $18.5M | ||
| Q1 24 | $12.7M | $7.2M |
自由现金流EGHTVCEL
| Q4 25 | $19.1M | $12.8M | ||
| Q3 25 | $7.7M | $19.5M | ||
| Q2 25 | $11.5M | $81.0K | ||
| Q1 25 | $5.5M | $-7.6M | ||
| Q4 24 | $26.8M | $8.5M | ||
| Q3 24 | $11.1M | $-9.2M | ||
| Q2 24 | $17.8M | $1.8M | ||
| Q1 24 | $12.3M | $-6.8M |
自由现金流率EGHTVCEL
| Q4 25 | 10.3% | 13.8% | ||
| Q3 25 | 4.2% | 28.8% | ||
| Q2 25 | 6.3% | 0.1% | ||
| Q1 25 | 3.1% | -14.5% | ||
| Q4 24 | 15.0% | 11.2% | ||
| Q3 24 | 6.1% | -15.9% | ||
| Q2 24 | 10.0% | 3.4% | ||
| Q1 24 | 6.9% | -13.3% |
资本支出强度EGHTVCEL
| Q4 25 | 0.9% | 2.4% | ||
| Q3 25 | 0.6% | 3.9% | ||
| Q2 25 | 0.2% | 12.9% | ||
| Q1 25 | 0.2% | 27.0% | ||
| Q4 24 | 0.3% | 18.3% | ||
| Q3 24 | 0.7% | 33.5% | ||
| Q2 24 | 0.2% | 31.8% | ||
| Q1 24 | 0.2% | 27.3% |
现金转化率EGHTVCEL
| Q4 25 | 4.07× | 0.65× | ||
| Q3 25 | 11.52× | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 9.01× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EGHT
| Services | $179.7M | 97% |
| Other | $5.4M | 3% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
